Short-Term Debt to Equity Ratio: Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) relies on the expertise of a staff of leading neurobiologists whose loyalty is secured through stock option programs. However, global instability and sanctions complicate the execution of cross-border trials, which slows down drug certification. The current metric stands at 0.00. Optimization of raw material supply chains supports high profitability, as confirmed by the price trajectory shown below for the securities of this company developing antidepressants.
Financial and market metric breakdowns for relmada.com (RLMD)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Relmada Therapeutics|RLMD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Relmada Therapeutics, Inc.|RLMD - Company Cumulative Debt|Debt to Book Capitalization Ratio Relmada Therapeutics Inc|RLMD - Company Long-Term Debt|Company Short-Term Debt Relmada Therapeutics|Quick Ratio relmada.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:RLMD Relmada
This ratio reflects the share of long-term credit obligations within the equity structure, allowing for an assessment of the business's financial stability and debt load. For Relmada Therapeutics (RLMD), which is incurring losses during the development stage of CNS drugs, the chart of the ratio between short-term liabilities and equity is critical for analyzing the company's ability to fund clinical trials until the commercialization of its patents.
Competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|DNLI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Short-Term Debt to Equity Amylyx AMLX|Trevi Corp - Short-Term Debt to Equity|PRAX - Short-Term Debt to Equity|anavex.com (AVXL) - Short-Term Debt to Equity Ratio|CBLL: Short-Term Debt to Capital|Prothena Biosciences (PRTA) - Short-Term Debt to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio ANNX (Annexon Biosciences Inc.)|Short-Term Debt to Capital OMER|Short-Term Debt to Capital neurogene.com (NGNE)|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA: Short-Term Debt to Equity Ratio|Scilex Holding Company, Inc. - Short-Term Loans to Capital Ratio|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. - Ratio of Short-Term Indebtedness to Capital|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Inhibikase Therapeutics Inc IKT|Short-Term Debt to Equity Cassava (SAVA)|ASRT (assertiotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital COYA (Coya Therapeutics)|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|OVID - Short-Term Debt to Equity|Current Liabilities to Equity ABOS|CRVO: Short-Term Debt to Capital|Current Liabilities to Capital Alterity Therapeutics Limited (ATHE)|Short-Term Debt to Equity Ratio CLNN|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Ratio JUNS (Jupiter Neurosciences)|Short-Term Loans to Capital Ratio ANVS|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|ANEW Medical, Inc. - Short-Term Debt to Capital|NeuroSense Therapeutics (NRSN) - Short-Term Debt to Equity Ratio|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|MTVA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity NeurAxis, Inc|HSDT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Equity NEUP (bionomics.com.au)|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|ATHA - Short-Term Debt to Equity Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|cyclerion.com (CYCN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Cortigent Medical CRGT|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|Short-Term Debt to Capital BrainStorm Cell Therapeutics Inc. (BCLI)|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|Ratio of Short-Term Indebtedness to Capital CHRO|ELYM - Short-Term Debt to Equity|Current Liabilities to Capital Intra-Cellular Therapies|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Short-Term Debt to Equity SNPX (Synaptogenix Inc.)|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL - Short-Term Debt to Equity Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|CERE - Short-Term Debt to Capital